RDUS News and Press, Radius Health Inc. From 10/25/23

St. Joe Company (The) (JOE) is expected to report for Q1 2024 Meta Platforms Inc. (META) is expected to report $3.62 for Q3 2023 Industrial Logistics Properties Trust (ILPT) is expected to report $0.11 for Q3 2023 Mid-America Apartment Communities Inc. (MAA) is expected to report $2.2...

Schnitzer Steel Industries Inc. (RDUS) is expected to report for Q4 2023

2023-10-24 12:22:17 ET More on Schnitzer Steel Radius Recycling: Holding After The Rebrand REITs gain on back of optimism surrounding strong economy REITs decline as rate hike concerns weigh on sentiments Seeking Alpha’s Quant Rating on Schnitzer Steel...

2023-10-18 07:27:41 ET Summary Radius Recycling has experienced management and a strong balance sheet, but there are risks related to commodity prices, the strength of the dollar, and potential impairments. Shares trading below $23 present a multi-year investment opportunity with ...

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2023 ended August 31, 2023 on Wednesday, October 25, 2023. The Company will host a webcast conference call to discuss the results at ...

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a...

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic compan...

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer Canada NewsWire Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available...

Sale Announcement Follows Successful Velan-Repertoire Campaign Featuring Three World-Class Director Candidates Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or &...

Urges stockholders to vote “ FOR ” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWI...